BAX vs SKYA vs MCK Stock Comparison

Baxter International, SkyAI and Mckesson Prices as of Nov 2, 2026 Peers: Industry group
1 more company in this comparison (ACU) Create a free account to keep reading and compare up to 10 companies.
BAX Baxter International Inc
$24.22 +3.1% 1M +31.1% 1Y
Market cap
$12.53B
P/E
–
Revenue (TTM)
$11.61B
Div. yield
0.17%
Medical Supplies Healthcare
1 win
SKYA SkyAI, Inc.
$2.93 +59.2% 1M -33.6% 1Y
Market cap
$211.23M
P/E
–
Revenue (TTM)
$194.22K
Div. yield
–
Medical Supplies Healthcare
2 wins
MCK Mckesson Corp
$998.79 +10.6% 1M +23.1% 1Y
Market cap
$116.45B
P/E
25.8x
Revenue (TTM)
$410.98B
Div. yield
0.34%
Drug Distribution Healthcare
8 wins

Head to Head

11 decided of 12

Mckesson leads on 8 of the 12 questions below (Mckesson 8, SkyAI 2, Baxter International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBAXSKYAMCKLeader
Larger companyMarket capitalisation $12.53B $211.23M $116.45B MCK
Cheaper on earningsLower P/E, profitable companies only -17.3x -0.7x 25.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 12.2x 0.0x 21.2x SKYA
Faster revenue growthRevenue growth, trailing twelve months +5.3% +108.9% +8.8% SKYA
More profitableNet margin, trailing twelve months -6.2% -158,431.4% 1.1% MCK
Better return on capitalReturn on invested capital -1.4% — 107.9% MCK
Less leveragedLower net debt / EBITDA 9.0x — 0.6x MCK
Higher dividend yieldTrailing dividend yield 0.17% — 0.34% MCK
Better 1-year returnPrice return, last 12 months +31.1% -33.6% +23.1% BAX
Better 5-year returnAnnualised price return, 5 years -21.3%/yr — +34.8%/yr MCK
Less volatileAnnualised volatility, 1 year 42.5% 105.5% 30.8% MCK
Higher overall scoreMean of the five percentile scores vs peers 44/100 26/100 60/100 MCK

Percentile Scorecard

BAXSKYAMCK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBAXSKYAMCK
Valuation 88 #29 of 227 2 #222 of 227 50 #13 of 25
Growth 14 #189 of 220 7 #205 of 220 65 #9 of 24
Profitability 65 #73 of 209 1 #207 of 209 70 #8 of 24
Financial Health 18 #198 of 240 95 #14 of 240 48 #14 of 26
Shareholder Returns 34 #91 of 138 – 69 #6 of 17
Overall 44 26 60
  • BAX ranked among 247 companies in Medical Devices and Diagnostics
  • SKYA ranked among 247 companies in Medical Devices and Diagnostics
  • MCK ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBAXSKYAMCKSPY
1 month +3.1%+59.2%+10.6% -2.3%
3 months -13.8%+127.1%+21.1% -0.7%
6 months +45.7%+60.1%+23.6% +4.8%
Year to date +26.7%+44.3%+21.8% +10.3%
1 year +31.1%-33.6%+23.1% +10.3%
3 years -28.7%-99.9%+120.6% +73.0%
3 years, per year -10.7%-90.1%+30.2% +20.1%
5 years -69.7%—+345.4% +61.9%
5 years, per year -21.3%—+34.8% +10.1%
10 years -48.2%—+635.3% +258.6%
10 years, per year -6.4%—+22.1% +13.6%

Risk

MeasureBAXSKYAMCKSPY
Volatility, 1Y 42.5%105.5%30.8% 12.8%
Downside volatility, 1Y 44.1%104.8%27.4% 12.8%
Beta vs S&P 500, 1Y 1.072.49-0.27 1.00
Return / volatility, 1Y 0.73-0.320.75 0.80
Max drawdown, 5Y -82.3%-100.0%-27.2% -25.4%
From 52-week high -14.6%-31.5%-3.0% -3.5%
52-week high $28.35$4.28$1,030.18 $779.14
52-week low $15.80$0.95$725.17 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBAXSKYAMCK
P/E now vs peer median -17.3xmedian 28.4x -0.7xmedian 28.4x 25.8xmedian 24.6x
P/S now vs peer median 1.1xmedian 3.0x 1,088xmedian 3.0x 0.3xmedian 0.3x
EV/EBITDA now vs peer median 26.1xmedian 18.0x —median 18.0x 16.7xmedian 13.2x
P/FCF now vs peer median 10.8xmedian 25.0x —median 25.0x 18.1xmedian 16.5x
P/B now vs peer median 1.9xmedian 2.3x 1.3xmedian 2.3x -27.5xmedian 2.5x
PEG now vs peer median 0.55median 0.93 0.01median 0.93 2.16median 1.39

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBAXSKYAMCK
Revenue $11.61B $194.22K $410.98B
Gross profit $3.49B $321.93K $14.96B
Operating income -$221.00M -$289.52M $6.50B
Net income -$723.00M -$307.71M $5.30B
Free cash flow $1.16B – $6.42B
R&D $519.00M $399.91K –
EPS (diluted) $-1.39 $-4.27 $38.52
Cash & equivalents $1.98B $12.07M $5.16B
Total debt $8.60B – $9.73B
Shares (diluted) 520.00M 72.09M 119.20M
Enterprise value $4.38B $169.94M $102.91B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBAXSKYAMCK
P/E -17.3x -0.7x 25.8x
P/FCF 10.8x – 18.1x
P/Operating cash flow 7.5x – 17.0x
P/S 1.1x 1,088x 0.3x
P/B 1.9x 1.3x -27.5x
P/Tangible book 4.9x 16.3x -14.1x
EV/EBITDA 26.1x – 16.7x
EV/EBIT -86.7x -0.7x 18.6x
EV/Revenue 1.6x 1,025x 0.3x
EV/FCF 16.5x – 18.9x
EV/Operating cash flow 11.5x – 17.7x
PEG (3Y EPS CAGR) 0.55 0.01 2.16

Growth

14 metrics
MetricBAXSKYAMCK
Revenue growth (1Y) 5.3% 108.9% 8.8%
Revenue CAGR (3Y) 0.7% 23.8% 13.1%
Gross profit growth (1Y) -7.1% – 11.2%
Gross profit CAGR (3Y) -7.7% – 6.6%
Operating income growth (1Y) -136.3% -5,525% 46.6%
Operating income CAGR (3Y) 4.2% -212.8% 13.5%
Net income growth (1Y) -112.0% -42,440% 58.1%
Net income CAGR (3Y) -31.6% -238.0% 10.7%
EPS growth (1Y) -109.6% -487.2% 52.8%
EPS CAGR (3Y) -31.5% -84.2% 12.0%
Operating cash flow growth (1Y) 97.4% – 4.7%
Operating cash flow CAGR (3Y) 0.6% – 10.7%
Free cash flow growth (1Y) 243.5% – 6.8%
Free cash flow CAGR (3Y) -5.0% – 11.3%

Profitability

14 metrics
MetricBAXSKYAMCK
Gross margin 30.1% 165.8% 3.6%
EBITDA margin 6.3% – 1.8%
Operating margin -1.9% -149,065% 1.6%
Pretax margin -1.6% -151,352% 1.6%
Net margin -6.2% -158,431% 1.1%
FCF margin 10.0% – 1.6%
Operating cash flow margin 14.3% – 1.7%
Return on equity -11.4% -140.2% –
Return on assets -3.7% -137.6% 6.2%
Return on invested capital -1.4% – 107.9%
Return on capital employed -1.4% -136.7% 43.4%
Asset turnover 0.6x 0.0x 4.8x
Cash conversion (OCF / net income) -2.3x – 1.3x
Stock comp / revenue 0.9% 48,037% –

Financial Health

11 metrics
MetricBAXSKYAMCK
Debt / assets 44.3% – 11.0%
Debt / equity 1.3x – -2.3x
Net debt / EBITDA 9.0x – 0.6x
Debt / FCF 7.4x – 1.5x
Liabilities / assets 66.5% 1.9% 104.8%
Equity / assets 33.5% 98.1% -4.8%
Interest coverage – – 23.6x
Current ratio 1.8x 5.3x 0.9x
Quick ratio 1.0x 4.4x 0.5x
Cash ratio 0.5x 4.2x 0.1x
Altman Z-score 2.35 31.69 5.91

Shareholder Returns

7 metrics
MetricBAXSKYAMCK
Dividend yield 0.2% – 0.3%
Net buyback yield -0.2% – 5.7%
Shareholder yield 0.0% – 6.0%
Payout ratio (earnings) -14.1% – 7.4%
Payout ratio (FCF) 8.8% – 6.1%
Dividend growth (1Y) -75.0% – 11.3%
Dividend CAGR (3Y) -44.1% – 10.0%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBAXSKYAMCK
Forward P/E 12.2xFY2026 0.0xFY2026 21.2xFY2026
EPS, next fiscal year $1.98FY2026 $2,362.06FY2026 $47.15FY2026
EPS growth, next FY -10.4%FY2026 – +20.6%FY2026
EPS growth, the year after -3.5% – +11.0%
Revenue, next fiscal year $11.05BFY2026 $70.01MFY2026 $444.47BFY2026
Revenue growth, next FY -1.7%FY2026 +34,200.1%FY2026 +10.2%FY2026
Revenue growth, the year after +11.7% +17.5% +1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBAXSKYAMCK
Held by institutions 100.0% – 89.1%
Institutions holding 692 – 2,012
Change in shares held, QoQ +5.2% – -0.7%
Institutions buying 359 – 883
Institutions selling 194 – 792
Buyers to sellers 1.85 – 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BAXSKYAMCK
BAX 1.00 0.08 0.18
SKYA 0.08 1.00 -0.10
MCK 0.18 -0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BAX, SKYA and MCK?

Mckesson (MCK) is the largest by market capitalisation: Baxter International (BAX) $12.53B, SkyAI (SKYA) $211.23M, Mckesson (MCK) $116.45B.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: Baxter International (BAX) +5.3%, SkyAI (SKYA) +108.9%, Mckesson (MCK) +8.8%.

Which company is more profitable?

Mckesson (MCK) has the highest net margin (Baxter International (BAX) -6.2%, SkyAI (SKYA) -158,431.4%, Mckesson (MCK) 1.1%). On return on invested capital, Mckesson (MCK) leads (Baxter International (BAX) -1.4%, Mckesson (MCK) 107.9%).

Which stock has performed better?

Over the past year Baxter International (BAX) returned the most: Baxter International (BAX) +31.1%, SkyAI (SKYA) -33.6%, Mckesson (MCK) +23.1%. Over five years, Mckesson (MCK) compounded fastest (Baxter International (BAX) -21.3%/yr, Mckesson (MCK) +34.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Mckesson (MCK) has the highest dividend yield: Baxter International (BAX) 0.17%, Mckesson (MCK) 0.34%. SkyAI (SKYA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Baxter International (BAX) 42.5%, SkyAI (SKYA) 105.5%, Mckesson (MCK) 30.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BAX, SKYA and MCK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.